Literature DB >> 18751708

[Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].

H Moch1.   

Abstract

Germ line inactivation of the von-Hippel-Lindau (VHL) tumor suppressor gene causes von Hippel-Lindau hereditary cancer syndrome, and somatic mutations of this gene have been linked to the development of sporadic hemangioblastomas and clear cell renal carcinomas. The protein encoded by VHL, pVHL, has no known enzymatic activities but interacts with various partner proteins. In this review, various pVHL functions are highlighted. pVHL acts as a multi-purpose adaptor protein that controls different gene expression programs. Through its oxygen-dependent regulation of hypoxia-inducible factor alpha (HIFalpha), pVHL plays a central role in the oxygen-sensing pathway. In addition, many HIFalpha-independent functions of pVHL have recently been identified. These include microtubule-based processes, extracellular matrix assembly and suppression of kidney cyst formation. These complex pVHL functions can explain the diverse consequences of pVHL dysregulation in tumor formation and progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18751708     DOI: 10.1007/s00292-008-1034-y

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  31 in total

1.  The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance.

Authors:  Claudio R Thoma; Ian J Frew; Wilhelm Krek
Journal:  Cell Cycle       Date:  2007-05-25       Impact factor: 4.534

Review 2.  Cilia and disease.

Authors:  Lorraine Eley; Laura M Yates; Judith A Goodship
Journal:  Curr Opin Genet Dev       Date:  2005-06       Impact factor: 5.578

3.  Hypoxia requires notch signaling to maintain the undifferentiated cell state.

Authors:  Maria V Gustafsson; Xiaowei Zheng; Teresa Pereira; Katarina Gradin; Shaobo Jin; Johan Lundkvist; Jorge L Ruas; Lorenz Poellinger; Urban Lendahl; Maria Bondesson
Journal:  Dev Cell       Date:  2005-11       Impact factor: 12.270

4.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

5.  p53 stabilization and transactivation by a von Hippel-Lindau protein.

Authors:  Jae-Seok Roe; Hyungsoo Kim; Soon-Min Lee; Sung-Tae Kim; Eun-Jung Cho; Hong-Duk Youn
Journal:  Mol Cell       Date:  2006-05-05       Impact factor: 17.970

6.  pVHL and GSK3beta are components of a primary cilium-maintenance signalling network.

Authors:  Claudio R Thoma; Ian J Frew; Christian R Hoerner; Matteo Montani; Holger Moch; Wilhelm Krek
Journal:  Nat Cell Biol       Date:  2007-04-22       Impact factor: 28.824

Review 7.  p53: guardian of the genome and policeman of the oncogenes.

Authors:  Alejo Efeyan; Manuel Serrano
Journal:  Cell Cycle       Date:  2007-05-28       Impact factor: 4.534

8.  Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia.

Authors:  Ian J Frew; Andrea Minola; Strahil Georgiev; Manuela Hitz; Holger Moch; Stéphane Richard; Alexander O Vortmeyer; Wilhelm Krek
Journal:  Mol Cell Biol       Date:  2008-05-12       Impact factor: 4.272

Review 9.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

10.  Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma.

Authors:  B R Seizinger; G A Rouleau; L J Ozelius; A H Lane; G E Farmer; J M Lamiell; J Haines; J W Yuen; D Collins; D Majoor-Krakauer
Journal:  Nature       Date:  1988-03-17       Impact factor: 49.962

View more
  1 in total

1.  Hypoxia-regulated lncRNA CRPAT4 promotes cell migration via regulating AVL9 in clear cell renal cell carcinomas.

Authors:  Wenhua Zhang; Jue Wang; Rong Chai; Guangxin Zhong; Cong Zhang; Wenjia Cao; Lei Yan; Xiang Zhang; Zhonghua Xu
Journal:  Onco Targets Ther       Date:  2018-08-03       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.